Escolar Documentos
Profissional Documentos
Cultura Documentos
Review article
BDH-Klinik Greifswald, Germany and 2Department I of Internal Medicine, Clinical Trials Centre Cologne, ZKS Koln, BMBF, Center for Integrated Oncology CIO
KolnBonn, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), German Centre for Infection Research, University of
Cologne, Cologne, Germany
Summary
Introduction
Candidaemia is a potentially devastating bloodstream
infection with Candida spp. predominantly affecting
hospitalised, severely ill patients. Candida spp. has been
implicated in up to 9% of cases in a large survey of over
24000 blood stream infections.1 Major risk factors for
candidaemia in non-neutropenic patients include gastrointestinal perforation, recent abdominal surgery,
prolonged stay on intensive care units, compromised
immune system, treatment with broad spectrum antibacterial agents, malignant diseases, organ dysfunction,
the extremes of age, central venous catheters and
Candida colonisation. Despite substantial advances in
antifungal agents and treatment strategies, candidaemia remains associated with high mortality. The
overall mortality is reported at 3060% and attributable
mortality rates of 2540% have been estimated.16
Correspondence: A. Glockner, BDH-Klinik Greifswald, Karl-Liebknecht-Ring
26a, 17491 Greifswald, Germany.
Tel.: +4 938 348 71231. Fax: +4 938 348 71226.
E-mail: a.gloeckner@bdh-klinik-greifswald.de
doi:10.1111/j.1439-0507.2012.02208.x
Table 1 Therapeutic recommendations for candidaemia in non-neutropenic adult patients without upfront information on Candida species
and or susceptibility.
IDSA [9]
Indication for
antifungal therapy
Preferred first line
therapy
Only EC as
recommended first
line therapy
14 d after end of
candidaemia
No statement
Recommended, with
daily sampling
No statement
After 10 d of IV therapy if
FLC-susceptible species
oral therapy tolerated
patient stable
Recommended in pts
receiving azoles or
AMB-D
Not recommended for
pts treated with EC
or L-AMB
Recommended
Duration of
therapy
Blood culture
monitoring on
therapy
Step down therapy
to oral fluconazole
Catheter
removal
Strongly
recommended
Recommended (always
if C. parapsilosis
detected)
Fundoscopy
Recommended; within
the first week of therapy
No statement
Recommended
No statement on
frequency
Optional after 10 d of IV
therapy if
negative blood cultures
proven susceptibility of
isolate
clinical stabilisation
ability to take oral
medication
unrestricted GI absorption
Recommended for all pts
pts, patients; EC, echinocandin; FLC, fluconazole; VORI, voriconazole; L-AMB, liposomal amphotericin B; IV, intravenous.
The current IDSA guidelines9 favour the use of echinocandins in moderately to severely ill patients without
giving a closer definition of these terms besides hemodynamic instability. Similarly, the ECIL-3 guidelines
discourage the use of fluconazole in severely ill
patients.11 The rationale behind these recommendations is recent data showing improved outcomes of
candidaemia in patients with early adequate therapy,
particularly in those with severe sepsis. As echinocandins have a broader spectrum of antifungal activity and
are considered fungicidal against many Candida isolates,
this class of antifungals should be preferred in critically
ill patients.
Traditionally, patients with hemodynamic instability,
i.e. those requiring vasopressors were considered as
being at highest risk for unfavourable outcomes of
candidaemia invasive candidiasis. However, this approach may be too narrow as it focuses on one single
systemic hallmark of severe infection. Rather the full
clinical picture and organ dysfunction pattern should be
considered.
Candidaemia patients with acute failure of one or
more organs should generally be considered as being
severely ill. Consequently, all patients treated on
intensive care units should be included into this
category and thus receive an echinocandin as the
primary treatment.
A randomised study comparing anidulafungin vs.
fluconazole for candidaemia showed a significantly
higher global success rate in the total population for
the echinocandin.19 In subgroup analyses, patients with
organ dysfunction (lung, kidney, liver or cardiovascular) had consistently higher global success rates in the
anidulafungin group.20 The difference was significant
for patients with APACHE II scores >15 and those with
severe sepsis and multiorgan dysfunction.20
On the basis of the results of this study 19 and the
cumulative experience with this class of antifungals
the EFISG panel chose to recommend echinocandins as
the class of choice (recommendation grade A; evidence
grade I) for primary targeted therapy of candidaemia in
all patients.11 We agree with the recommendation of
the EFISG, where fluconazole is no longer considered a
preferred option for the targeted initial treatment
of candidaemia. Its use is only marginally recommended (grade CI) due to its therapeutic inferiority to
anidulafungin.11
Catheter management
As stated in the IDSA guidelines and confirmed by
similar recommendations of ECIL and DMYKG PEG a
central venous catheter (CVC) should be removed in
patients with candidaemia whenever possible, given the
role of catheters as a reservoir for Candida spp. in
biofilms33,34 and a potential source for persistent
candidaemia.35
Analyses of data from recent studies and several older
investigations suggested more favourable outcomes;
lower mortality and shorter duration of candidaemia
in patients who have their CVC removed early, i.e.
72 h after onset of candidaemia.3640 On the basis of
this evidence, the EFISG as well recommends the
removal of indwelling vascular access lines at least for
patients receiving azoles or amphotericin B deoxycholate (grade BII).11 For patients receiving echinocandins
this may not be as crucial as removal of indwelling
Duration of therapy
On the basis of the treatment duration defined in the
protocols of clinical trials, the guidelines recommend
duration of therapy of two weeks (14 days) after (i) the
resolution of symptoms and (ii) the end of candidaemia
whereas the latter is not uniformly defined. The most
unequivocal definition is the first negative blood
culture as stated in the guidelines of IDSA and
DMykG PEG.12 The criterion of the last positive blood
culture is less robust as it depends in the frequency of
blood culture sampling. We therefore prefer using the
time of blood sampling for the first negative blood
culture as the starting point for the residual 2 weeks of
therapy.
Step-down therapy
According to the IDSA guidelines it is reasonable to
switch (step down) patients from an echinocandin to
oral fluconazole if they have an initial fungal isolate
likely to be susceptible to fluconazole (e.g. C. albicans,
C. parapsilosis, C. tropicalis) and if they clinically improved after initial intravenous echinocandin therapy.9
Similarly, the EFISG considers a step down to oral
fluconazole feasible after 10 days of intravenous anti-
No adequate study data are available for the preemptive use of echinocandins in non-neutropenic
patients at high-risk of candidaemia before positive
blood culture results are available. Therefore no distinctions between the individual agents can be made for
this treatment situation.
Conclusions
Several recently published guidelines address the management of candidaemia in non-neutropenic adult
patients. While giving valuable guidance, the recommendations need to be interpreted in the light of the
actual clinical situation of a given patient.
Factors influencing the choice of initial therapy include
severity of illness, previous exposure to antifungals,
patient age, species of the initial isolate (if available) and
catheter issues. Antifungal therapy should be started
immediately after notification of positive blood cultures.
Pre-emptive antifungal therapy while awaiting a positive
Disclosure
The authors were involved in the preparation of the
following guidelines: OAC: EFISG, DMykG PEG; AG:
DMykG PEG. AG is a consultant to Astellas, MSD, Pfizer
and served at the speakers bureau of Astellas, MSD,
Pfizer.
OAC is supported by the German Federal Ministry of
Research and Education (BMBF grant 01KN1106), has
received research grants from Actelion, Astellas, Basilea, Bayer, Biocryst, Celgene, F2G, Genzyme, Gilead,
Merck/Schering, Miltenyi, Optimer, Pfizer, Quintiles,
and Viropharma, is a consultant to Astellas, Basilea,
F2G, Gilead, Merck/Schering, Optimer, and Pfizer, and
received lecture honoraria from Astellas, Gilead, Merck/
Schering, and Pfizer.
References
1 Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP,
Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide
surveillance study. Clin Infect Dis 2004; 39: 30917.
2 Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP.
Hospital-acquired candidemia. The attributable mortality
and excess length of stay. Arch Intern Med 1988; 148:
26425.
3 Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Effects of
nosocomial candidemia on outcomes of critically ill patients.
Am J Med 2002; 113: 4805.
4 Voss A, le Noble JL, Verduyn Lunel FM, Foudraine NA, Meis
JF. Candidemia in intensive care unit patients: risk factors for
mortality. Infection 1997; 25: 811.
5 Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C.
The epidemiology and attributable outcomes of candidemia in
adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005; 41: 12329.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38 Asmundsdottir LR, Erlendsdottir H, Gottfredsson M. Improving survival of patients with candidaemia: analysis of prognostic factors from a long-term, nationwide study in Iceland.
Scand J Infect Dis 2005; 37: 11120.
39 Stamos JK, Rowley AH. Candidemia in a pediatric population.
Clin Infect Dis 1995; 20: 571.
40 Rex JH, Bennett JE, Sugar AM et al. Intravascular catheter
exchange and duration of candidemia. NIAID Mycoses Study
Group and the Candidemia Study Group. Clin Infect Dis 1995;
21: 9946.
41 Nucci M, Silveira MI, Spector N et al. Risk factors for death
among cancer patients with fungemia. Clin Infect Dis 1998;
27: 10711.
42 Rodriguez D, Park BJ, Almirante B et al. Impact of early central venous catheter removal on outcome in patients with
candidaemia. Clin Microbiol Infect 2007; 13: 78893.
43 Velasco E, Bigni R. A prospective cohort study evaluating the
prognostic impact of clinical characteristics and comorbid
conditions of hospitalized adult and pediatric cancer patients
with candidemia. Eur J Clin Microbiol Infect Dis 2008; 27:
10718.
44 Weinberger M, Leibovici L, Perez S et al. Characteristics of
candidaemia with Candida-albicans compared with non-albicans Candida species and predictors of mortality. J Hosp Infect
2005; 61: 14654.
45 Nucci M, Anaissie E, Betts RF et al. Early removal of central
venous catheter in patients with candidemia does not improve
outcome: analysis of 842 patients from 2 randomized clinical
trials. Clin Infect Dis 2010; 51: 295303.
46 DiDone L, Oga D, Krysan DJ. A novel assay of biofilm antifungal activity reveals that amphotericin B and caspofungin
lyse Candida albicans cells in biofilms. Yeast 2011; 28: 5618.
47 Fiori B, Posteraro B, Torelli R et al. In vitro activities of anidulafungin and other antifungal agents against biofilms
10
48
49
50
51
52
53
54
55
56
57